Health & Medicinearticle2026-10-19

Genotype–phenotype analysis in 333 individuals with heterozygous variants in NFKB1

Open access0 citations

Abstract

Heterozygous germline variants in NFKB1 can be classified into variants with “known protein defect” and “unknown protein effect.” However, beyond this, NFKB1 variants may be additionally categorized into at least eight distinct variant classes. We conducted a literature review of 67 papers reporting on NFKB1 variants and included four additional individuals, carrying previously unreported NFKB1 variants. We identified 333 individuals with unique variants in NFKB1. Our compiled data revealed that there is no sex predilection, the penetrance—including all heterozygous carriers—was 78%, and the mean age of onset for the “known protein defect cohort” was 21.2 years. Individuals harboring variants with a known protein defect demonstrated a higher frequency of malignancies and autoimmune disorders. However, these individuals were less frequently classified as affected than individuals with variants with unknown protein defect. Carriers of whole NFKB1 gene deletions had a significantly higher penetrance to being designated as “affected,” but beyond this, the clinical manifestations did not differ between variant classes.

// Source

View paper (DOI)Open access versionOpenAlexJournal of Human ImmunityPublished 2026-10-19

Authors: Sophia Marie Armbruster, Andrés Caballero-Oteyza, Oliver Bartsch, Tiziana Lorenzini, Hassan Abolhassani, Samantha Chan, Luis Ignacio González‐Granado, Víctor García-Bustos, Marta Dafne Cabañero-Navalón, Nazanin Fathi, Nima Rezaei, Mathieu Fusaro, Roger Colobrán, Kaan Boztuǧ, Michele Proietti, Bodo Grimbacher

Institutions: Karolinska Institutet, Hebron University, Inserm, Centre National de la Recherche Scientifique, Johannes Gutenberg University Mainz, Research Institute Hospital 12 de Octubre, University of Freiburg, Vall d'Hebron Institut de Recerca, University Medical Center Freiburg, Medical University of Vienna, The Royal Melbourne Hospital, Cancer Research Institute of the Slovak Academy of Sciences, University Medical Center of the Johannes Gutenberg University Mainz, Université Fédérale de Toulouse Midi-Pyrénées, University Hospital Bonn, Hospital Universitari i Politècnic La Fe, Toulouse Mathematics Institute, Children's Medical Center, Université Toulouse III - Paul Sabatier, CeMM Research Center for Molecular Medicine, University Children's Hospital Zurich, St Anna Children's Hospital